We are live on ! Find out more
AC

Aisling Capital Portfolio holdings

AUM $45.3M
1-Year Est. Return 15.24%
This Fund
S&P 500
This Quarter Est. Return
+8.62%
1 Year Est. Return
-15.24%
3 Year Est. Return
+386.13%
5 Year Est. Return
+981.36%
10 Year Est. Return
–
AUM
$66.5M
AUM Growth
-$287M
Cap. Flow
-$289M
Cap. Flow %
-434.45%
Top 10 Hldgs %
100%
Holding
8
New
–
Increased
–
Reduced
–
Closed
4

Top Buys

No buys this quarter

Top Sells

Rank Stock Value
1
LOXO
Loxo Oncology, Inc
LOXO
+$286M
2
VRAY
ViewRay, Inc.
VRAY
+$2.21M
3
CMRX
Chimerix, Inc.
CMRX
+$1.22M
4
PTX
Pernix Therapeutics Holdings, Inc.
PTX
+$88K

Sector Composition

Rank Sector Weight
1 Healthcare 33.16%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
AIMT
1
DELISTED
Aimmune Therapeutics
AIMT
$44.5M 66.84%
1,990,000
– –
ADMA icon
2
ADMA Biologics
ADMA
$1.92B
$13.7M 20.55%
3,608,171
– –
ASXC
3
DELISTED
Asensus Surgical, Inc.
ASXC
$5.69M 8.55%
183,796
– –
CDTX
4
DELISTED
Cidara Therapeutics
CDTX
$2.71M 4.07%
51,057
– –
CMRX
5
DELISTED
Chimerix, Inc.
CMRX
– –
-472,943
Closed -$1.22M
VRAY
6
DELISTED
ViewRay, Inc.
VRAY
– –
-363,640
Closed -$2.21M
LOXO
7
DELISTED
Loxo Oncology, Inc
LOXO
– –
-2,038,920
Closed -$286M
PTX
8
DELISTED
Pernix Therapeutics Holdings, Inc.
PTX
– –
-210,000
Closed -$88K

Similar funds

SCPM
Sagard Capital Partners Management New York $46.7M AUM 23.43% 1-Year Est. Return
ZIM
ZPR Investment Management Orange City, Florida $46.8M AUM 2.45% 1-Year Est. Return
ACP
Aquiline Capital Partners New York $46.9M AUM 5.65% 1-Year Est. Return
INL
IPC/NYCG LLC New York $43.3M AUM 61.41% 1-Year Est. Return
CP
Clover Partners Dallas, Texas $43.1M AUM 4.09% 1-Year Est. Return
SAM
Sheffield Asset Management Chicago, Illinois $48.1M AUM 12.96% 1-Year Est. Return
JCM
Julex Capital Management Wellesley, Massachusetts $42.4M AUM 9.78% 1-Year Est. Return
GX
Greylock XII Menlo Park, California $51.9M AUM 11.52% 1-Year Est. Return

Aisling Capital's Q1 2019 Portfolio in Review

As of Q1 2019, Aisling Capital held 8 positions worth $66.5M, down 81% from $353M the previous quarter. Its ten largest holdings account for 100% of the portfolio.

Aisling Capital withdrew a net $289M in Q1 2019, closing 4 positions. Its most notable exit was Loxo Oncology, Inc, an estimated $286M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 33% of assets, down from 86% a quarter earlier.

  • Aisling Capital fully exited Loxo Oncology, Inc in Q1 2019, selling an estimated $286M.
  • Aisling Capital's ten largest holdings make up 100% of its $66.5M portfolio in Q1 2019.
  • Aisling Capital opened 0 new positions and closed 4 in Q1 2019.
  • Aisling Capital's portfolio value fell 81% quarter-over-quarter to $66.5M.

Based on Aisling Capital's 13F filing for Q1 2019, filed 7 May 2019.